

10  
Europäisches Patentamt  
European Patent Office  
Office européen des brevets

11 Publication number:

123 294  
A1

12 EUROPEAN PATENT APPLICATION

13 Application number: 84104456.3

14 Int. Cl. C 12 N 15/00  
C 12 P 21/00

15 Date of filing: 19.04.84

16 Priority: 22.04.83 US 487753

17 Date of publication of application:  
31.10.84 Bulletin 84/44

18 Designated Contracting States:  
AT BE CH DE FR GB IT LI LU NL SE

19 Applicant: Amgen  
1900 Oak Terrace Lane  
Thousand Oaks California 91320(US)

20 Inventor: Bitter, Grant A.  
3571 Calle Del Sol  
Thousand Oaks California 91320(US)

21 Representative: Brown, John David et al.  
FORRESTER & BOEHMERT Wildenmayerstrasse 40  
D-8000 München 22(DE)

22 Section of exogenous polypeptides from yeast.

23 Disclosed are recombinant methods and materials for use in securing production of exogenous (e.g., mammalian) polypeptides in yeast cells wherein hybrid precursor peptides susceptible to intracellular processing are formed and such processing results in secretion of desired polypeptides. In a presently preferred form, the invention provides transformation vectors with DNA sequences coding for yeast synthesis of hybrid precursor polypeptides comprising both an endogenous yeast polypeptide sequence (e.g., that of a precursor polypeptide associated with yeast-secreted mating factor  $\alpha$  and an exogenous polypeptide sequence (e.g., human  $\beta$ -endorphin). Transformation of yeast cells with such DNA vectors results in secretion of desired exogenous polypeptide (e.g., substances displaying one or more of the biological properties of  $\beta$ -endorphin).

EP 0 123 294 A1

## "SECRETION OF EXOGENOUS POLYPEPTIDES FROM YEAST"

BACKGROUND

5 The present invention relates generally to recombinant methods and materials for securing the microbial expression of exogenous genes coding for useful polypeptide products and for securing the recovery of such products from microbial cells. More particularly, 10 the present invention relates to the formation of exogenous polypeptides in yeast cells and to the secretion of desired polypeptide products so formed.

Numerous substantial advances have recently been made in the use of recombinant DNA methodologies 15 to secure the large scale microbial production of eukaryotic (e.g., mammalian) gene products in prokaryotic and eukaryotic cells grown in culture. In essence, these advances have generally involved the introduction into bacterial, yeast, and higher eukaryote "host" cell 20 cultures of DNA sequences coding for polypeptides which wholly or partially duplicate the sequences of amino acids present in biologically active polypeptides ordinarily produced only in minute quantities by, e.g., specialized mammalian tissue cells. The hoped-for result 25 of such introductions is the stable genetic transformation of the host cells so that the polypeptides coded for by the exogenous genes will be produced in quantity by the protein manufacturing apparatus of the cells.

It has long been the goal of workers in this field to devise methods and materials permitting not 30 only the expression and stable accumulation of exogenous polypeptides of interest in host cells but also the secretory transport of intact polypeptide products from host cell cytoplasmic spaces into microbial periplasmic spaces or, preferably, outside the cell into the surrounding medium.

With particular regard to the use of E.coli

bacterial cells as microbial hosts, it is known to attempt to secure expression of desired exogenous polypeptides as portions of so-called "fused" polypeptides 5 including, e.g., endogenous enzymatic substances such as  $\beta$ -lactamase. Such enzymes normally migrate or are intracellularly processed toward E.coli periplasmic spaces and the fusion polypeptides including enzyme sequences are more or less readily isolated therefrom. See, Talmadge, et al., PNAS (USA), 77, 3369-3373 (1980). 10 Extracellular chemical or enzymatic cleavage is employed to yield the desired exogenous polypeptides in purified form. See, e.g., U.S. Letters Patent No. 4,366,246 to Riggs. At present, no analogous methods have been found to be readily applicable to microbial synthetic processes involving lower eukaryotic host cells such as yeast 15 cells (e.g., Saccharomyces cerevisiae).

A considerable body of knowledge has developed concerning the manner in which mammalian gene products, especially small regulatory polypeptides, are produced. See, generally, Herbert, et al., Cell, 30, 1-2 (1982). 20 As one example, biosynthetic studies have revealed that certain regulatory peptides are derived from precursor proteins which are ten times the size or more than the biologically active peptides. This fact indicates that significant intracellular processing must take place prior to secretion of discrete active products by the cells. The peptides must be cut out of the precursor 25 and are sometimes chemically modified to active forms prior to secretion. Cleavage from precursors and chemical modifications such as glycosylation, phosphorylation and secretion are generally believed to occur in a well-defined order as newly synthesized proteins pass through the membranes of the endoplasmic reticulum, Golgi 30 complexes, and vesicles prior to secretion of biologically active fragments.

Studies of polypeptides secreted by yeast cells have indicated that at least somewhat analogous processing of precursor proteins occurs prior to secretion into yeast cell periplasmic spaces or outside the yeast cell wall. A very recent review article on this subject by Schekman, et al., appears at pages 361-393 in "The Molecular Biology of the Yeast *Saccharomyces*, Metabolism and Gene Expression", Cold Spring Harbor Press (1982). Briefly put, the review article and the references cited therein indicate that eleven endogenous yeast polypeptide products have been identified which are secreted either into the periplasmic space or into the cellular medium or, on occasion, into both. Among the yeast polypeptides ordinarily secreted into the cellular growth medium are two yeast pheromones, mating factor  $\alpha$  and  $\alpha$ , pheromone peptidase, and "killer toxin". Among the yeast polypeptides ordinarily only transported to periplasmic spaces are Invertase, L-asparaginase, and both the repressible and constitutive forms of acid phosphatase. Yeast products which have been isolated both from the periplasmic space and yeast cell culture medium include  $\alpha$ -galactosidase, exo-1,3- $\beta$ -glucanase, and endo-1,3- $\beta$ -glucanase. The mechanisms which determine cell wall or extracellular location have not yet been elucidated.

The processing prior to secretion of certain of these polypeptides has been studied and it has generally been found that the products are initially expressed in cells in the form of precursor polypeptides having amino terminal regions including "signal" sequences (i.e., sequences of from 20-22 relatively hydrophobic amino acid residues believed to be functional in transport to the endoplasmic reticulum) and, in at least some instances, "pro" or "pre" sequences which are also ordinarily proteolytically cleaved from the portion of the precursor molecule to be secreted. See, Thill, et al., *Mol. & Cell. Biol.*, 3, 570-579 (1983).

With the knowledge that yeast cells are capable of intracellular processing of endogenous precursor polypeptides in a manner analogous to the processing carried out in mammalian cell systems, studies were recently conducted concerning the potential for secretion of human interferons by yeast. See, Hitzeman, et al., *Science*, 219, 620-625 (1983). Briefly put, transformation vectors were constructed which included DNA sequences coding for synthesis of human interferons in the yeast *Saccharomyces cerevisiae*. It was reported that expression of interferon genes containing coding sequences for human "secretion signals" resulted in the secretion into the yeast cell culture medium of polypeptide fragments having interferon immunological activity. While the levels of interferon activity found in the medium were quite low and a significant percentage of the secreted material was incorrectly processed, the results of the studies were said to establish that lower eukaryotes such as yeast can rudimentarily utilize and intracellularly process human signal sequences in the manner of endogenous signal sequences.

Of particular interest to the background of the present invention is the developing body of information available concerning the synthesis and secretion of the yeast oligopeptide pheromone, or mating factor, commonly referred to as mating factor  $\alpha$  ("MF $\alpha$ "). Mating in yeast appears to be facilitated by oligopeptide pheromones (mating factors) of two types,  $\alpha$  and  $\alpha$ , that cause the arrest of cells of the opposite type in the G1 phase of the cell division cycle. Yeast cells of the  $\alpha$  mating type produce MF $\alpha$  in tripeptide and dodecapeptide forms which differ on the basis of the presence or absence of a terminal tryptophan residue, while cells of the  $\alpha$  type produce MF $\alpha$  in two alternative undecapeptide forms which differ in terms of the identity of the sixth amino acid residue.

The structure of the yeast MFa gene has recently been the subject of study by Kurjan, et al., as reported in *Cell*, 30, 933-943 (1982). Briefly put, segments of yeast genomic DNA were inserted into a high copy number plasmid vector (YEpl3). The vectors were employed to transform mutant *mat<sup>α2</sup>*, *leu2* yeast cells which failed to secrete MFa and the culture medium was assayed for the "restoration" of MFa secretory activity. Those plasmids including a 1.7kb *EcoRI* fragment together with one or more genomic *EcoRI* fragments of lesser size were able to restore MFa secretory function. Sequencing of portions of the 1.7kb *EcoRI* fragment revealed that the cloned segment includes DNA sequences coding for four, spaced-apart copies of MFa within a putative precursor polypeptide which extends for a total of 165 amino acids.

The amino terminal region of the putative precursor delineated by Kurjan, et al., begins with a hydrophobic sequence of about 22 amino acids that presumably acts as a signal sequence for secretion. A following segment of approximately sixty amino acids contains three potential glycosylation sites. The carboxyl terminal region of the precursor contains four tandem copies of mature alpha factor, each preceded by a "spacer" peptides of six or eight amino acids, which are hypothesized to contain proteolytic processing signals.

The putative protein-coding region within the approximately 830 base pair sequence of the MFa gene published is as follows:

TABLE I

1	10	20	30	40
ATG AGA TTT CCT TCA ATT TTT ACT GCA GTT TTA TTC GCA GCA				
Met Arg Phe Pro Ser Ile Phe Thr Ala Val Leu Phe Ala Ala				
1	50	60	70	80
TCC TCC GCA TTA GCT GCT CCA GTC AAC ACT ACA ACA GAA GAT				
Ser Ser Ala Leu Ala Ala Pro Val Asn Thr Thr Thr Glu Asp				
35			20	

90	100	110	120
GAA ACG GCA CAA ATT CCG GCT GAA GCT GTC ATC GGT TAC TCA			
Glu Thr Ala Gln Ile Pro Ala Glu Ala Val Ile Gly Tyr Ser			
30	140	150	160
130	170	180	190
GAT TTA GAA GGG GAT TTC GAT GTT GCT GTT TTG CCA TTT TCC			
Asp Leu Glu Glu Gly Asp Phe Asp Val Ala Val Leu Pro Phe Ser			
5	200	210	
170	180	190	200
AAC AGC ACA AAT AAC GGG TTA TTG TTT ATA AAT ACT ACT ATT			
Asn Ser Thr Asn Asn Gly Leu Leu Phe Ile Asn Thr Thr Ile			
60	220	230	240
220	230	240	250
GCC AGC ATT GCT GCT AAT GAA GAA GGG GTA TCT TTG GAT AAA			
Ala Ser Ile Ala Ala Lys Lys Glu Gly Val Ser Leu Asp Lys			
80	260	270	280
260	270	280	290
AGA GAG GCT GAA GCT TGG CAT TGG TTG CAA CTA AAA CCT GGC			
15	300	310	320
Arg Glu Ala Glu Ala Trp His Trp Leu Gln Leu Lys Pro Gly			
90	300	310	320
300	310	320	330
CAA CCA ATG TAC AAG AGA GAA GCC GAA GCT GAA GCT TGG CAT			
Gln Pro Met Tyr Lys Arg Glu Ala Glu Ala Glu Ala Trp His			
102	340	350	360
340	350	360	370
TGG CTG CAA CTA AAG CCT GGC CAA CCA ATG TAC AAA AGA GAA			
Trp Leu Gln Leu Lys Pro Gly Gln Pro Met Tyr Lys Arg Glu			
123	380	390	400
380	390	400	410
GCC GAC GCT GAA GCT TGG CAT TGG CTG CAA CTA AAG CCT GGC			
Ala Asp Ala Glu Ala Trp His Trp Leu Gln Leu Lys Pro Gly			
132	420	430	440
420	430	440	450
CAA CCA ATG TAC AAA AGA GAA GCC GAC GCT GAA GCT TGG CAT			
Gln Pro Met Tyr Lys Arg Glu Ala Asp Ala Glu Ala Trp His			
144	460	470	480
460	470	480	490
TGG TTG CAG TTA AAA CCC GGC CAA CAA ATG TAC TAA			
30	500	510	520
Trp Leu Gln Leu Lys Pro Gly Gln Pro Met Tyr Stop			
165			

As previously noted, the MFa gene described in Kurjan, et al., *supra*, is contained on a 1.7 kilobase *EcoRI* yeast genomic fragment. Production of the gene 35 product is inactivated by cleavage with the endonuclease *HindIII* and it was noted that *HindIII* digestion yielded

small fragments generally including the following coding regions:  $\alpha$  factor 1 (amino acids 90-102), spacer 2;  $\alpha$  factor 2 (amino acids 111-123), spacer 3;  $\alpha$  factor 3 (amino acids 132-144), spacer 4; spacer 1 and  $\alpha$  factor 4 amino acids 153-165) remain on large fragments.

Thus, each MFa coding region in the carboxyl terminal coding region is preceded by a six or eight codon "spacer" coding region. The first of the spacers coded for has the sequence, -NH-Lys-Arg-Glu-Ala-Glu-Ala-COO-, while the second has the sequence, -NH-Lys-Arg-Glu-Ala-Glu-Ala-COO-. The third and fourth spacers coded for have the same sequence of amino acid residues, i.e., -NH-Lys-Arg-Glu-Ala-Asp-Ala-Glu-Ala-COO-.

Among the proposals of Kurjan, et al. as to the mode of processing of the MFa precursor polypeptide leading up to secretion of MFa was that the precursor was targeted for processing in the endoplasmic reticulum by the putative 22 hydrophobic amino acid "signal" sequence in the amino terminal region of the precursor (amino acids 1-22). The post-targeting fate of the sequence was proteolytic cleavage from the remaining portions of the precursor. The following "pro" sequence of about 60 amino acids (residues 23-83) was proposed to be involved in subsequent targeting of the precursor for further processing and to an eventual fate similar to that of the "signal". Finally, it was proposed that the multiple copies of MFa were first separated by a trypsin-like enzymatic cleavage between the lysine and arginine residues at the beginning of each "spacer"; that the residual lysine at the carboxyl terminal of all but the fourth MFa copy was digested off by a yeast carboxy peptidase; and that diaminopeptidase enzymes would proteolytically delete the remaining "spacer" residues from the amino terminal of at least one of the four MFa copies.

While the work of Kurjan, et al. served to provide much valuable information and many valuable proposals concerning MFa synthesis and secretion in yeast, many questions significant to application of the information to systems other than those specifically involving MFa secretion remained unanswered. Among these was whether the above-noted 1.7kb EcoRI yeast genome fragment provides a self-contained sequence capable of directing synthesis of MFa (i.e., whether it included the entire endogenous promoter/regulator for precursor synthesis or, on the other hand, required the presence of other DNA sequences). Other unanswered questions included whether the presence of DNA "repeats" was required for MFa expression, whether the specific size of the MFa polypeptide is a critical factor in secretory processing events, and whether all potential copies of MFa in the precursor polypeptide are in fact secreted by yeast cells.

A recent publication by Julius, et al., Cell, 32, 839-852 (1983) serves to partially confirm the MFa precursor hypothesis of Kurjan, et al. in noting that mutant yeast strains defective in their capacity to produce certain membrane-bound, heat-stable dipeptidyl diaminopeptidase enzymes (coded for by the "stel3" gene) secrete incompletely processed forms of MFa having additional amino terminal residues duplicating "spacer" sequences described by Kurjan, et al. Restoration of the mutants' capacity to properly process MFa was demonstrated upon transformation of cells with plasmid-borne copies of the non-mutant form of the stel3 gene.

From the above description of the state of the art, it will be apparent that there continues to exist a need in the art for methods and materials for securing microbial expression of exogenous polypeptide products accompanied by some degree of intracellular secretory processing of products facilitating the isola-

tion of products in purified form. Despite varying degrees of knowledge concerning synthesis and processing of yeast-secreted polypeptides and despite some preliminary success in procedures involving yeast secretory processing of exogenous gene products in the form of exogenous precursor polypeptides, the art has been provided with no procedures which take joint advantage of yeast cell capacities both to synthesize exogenous gene products and to properly process endogenous precursor polypeptides in a manner permitting exogenous gene products to be secreted by transformed yeast cells.

#### BRIEF SUMMARY

According to one aspect of the invention, there are provided DNA sequences which code for yeast cell synthesis of novel hybrid polypeptides including, in one part, selected exogenous polypeptide amino acid sequence and, in another part, certain endogenous yeast polypeptide amino acid sequences. More particularly, the hybrid polypeptides coded for by DNA sequences of the present invention include, in their carboxyl terminal region, an exogenous polypeptide to be secreted by the yeast cells in which the hybrids are synthesized. Further, a portion of the amino terminal region of the hybrid polypeptides includes sequences of amino acids which duplicate "signal" or "pro" or "pre" sequences of amino terminal regions of endogenous polypeptide precursors of yeast-secreted polypeptides (which sequences are normally proteolytically cleaved from the endogenous precursors prior to polypeptide secretion into periplasmic spaces or into the yeast cell culture medium).

In another of its aspects, hybrid polypeptides coded for by DNA sequences of the invention may also include (normally proteolytically-cleaved) endogenous

yeast polypeptide sequences in their carboxyl terminal regions as well.

Endogenous yeast DNA sequences duplicated in hybrid polypeptides of the invention may be those extant in polypeptide precursors of various yeast-secreted polypeptides such as mating factor  $\alpha$ , mating factor  $\beta$ , killer toxin, invertase, repressible acid phosphatase, constitutive acid phosphatase,  $\alpha$ -galactosidase, L-asparaginase, exo-1,3- $\beta$ -glucanase, endo-1,3- $\beta$ -glucanase and peromone peptidase. In presently preferred forms, DNA sequences of the invention code for hybrid polypeptides including endogenous polypeptides which duplicate one or more amino acid sequences found in polypeptide precursors of yeast-secreted Mfa. The duplicated sequences may thus include part or all of the Mfa precursor "signal" sequence; part or all of the Mfa "pro" sequence; and/or part or all of one or more of the variant Mfa "spacer" sequences as described by Kurjan, et al., *supra*.

Exogenous polypeptide constituents of hybrid polypeptides according to the invention may be of any desired length or amino acid sequence, with the proviso that it may be desirable to avoid sequences of amino acids which normally constitute sites for proteolytic cleavage of precursor polypeptides of yeast-secreted polypeptides. In an illustrative and presently preferred embodiment of the invention, an exemplary novel DNA sequence constructed codes for a hybrid polypeptide including, in its carboxyl terminal region, a human  $\beta$ -endorphin polypeptide.

According to another aspect of the invention, DNA transformation vectors are constructed which incorporate the above-noted novel DNA sequences. These vectors are employed to stably genetically transform yeast cells which are then grown in culture under conditions facilitating expression of desired hybrid polypeptides. The desired hybrids are, in turn, intracellularly

genomic library and the partial sequencing of the cloned fragment; (2) the construction of a DNA sequence coding for human  $\beta$ -endorphin; (3) the ligation of the  $\beta$ -endorphin coding DNA sequence into the Mfu structural gene; (4) the insertion of the resulting DNA sequence into a transformation vector; (5) the transformation of yeast cells with the resulting vector; (6) the isolation and characterization of polypeptide products secreted into the culture medium by transformed cells; and (7) the construction of an alternative transformation vector.

#### EXAMPLE 1

A Saccharomyces cerevisiae genome library in E.coli was screened with a synthetic oligonucleotide hybridization probe, and a plasmid with complementarity to the probe was cloned. From this cloned plasmid a 2.1kb EcoRI fragment with complementarity to the probe was subcloned in pBR322. The oligonucleotide probe used duplicates the sequence of bases later designated 474 through 498 of the sense strand DNA sequence set out in Figure 5 of Kurjan, et al., supra. Approximately 500 base pairs of the isolated fragment were initially sequenced by Maxam-Gilbert and dideoxy chain termination techniques and found to be essentially identical to the sequence of the protein coding region of an Mfu structural gene set out by Kurjan, et al., supra. The 2.1kb fragment was digested with XbaI. The larger, 1.7kb digestion fragment obtained was ligated to a BamHI "linker" DNA sequence and inserted into an E.coli bacterial plasmid (pBR322, i.e., pBR322 which had been modified to delete the HindIII site) cut with BamHI. The resulting plasmid, designated pFc, was amplified.

35

processed with the result that desired exogenous polypeptide products are secreted into yeast cell periplasmic spaces and/or outside the yeast cell wall into the yeast cell culture medium. In vectors of the present invention, expression of the novel DNA sequences may be regulated by any suitable promoter/regulator DNA sequence.

Illustrative examples of DNA transformation vectors of the invention include plasmids pYcE and pYcE on deposit under contract with the American Type Culture Collection, Rockville, Maryland, as ATCC Nos. 40068 and 40069, respectively. Both these plasmids include hybrid polypeptide coding regions under control of promoter/regulator sequences duplicating those associated with genomic expression of Mfu by yeast cells. Plasmid pYcE (ATCC No. 40068) may be employed according to the present invention to transform a suitable Saccharomyces cerevisiae cell line (e.g., any  $\alpha$ , leu2 strain such as GM3C-2) and the cultured growth of cells so transformed results in the accumulation, in the medium of cell growth, of polypeptide products possessing one or more of the biological activities (e.g., immunoreactivity) of human  $\beta$ -endorphin.

Other aspects and advantages of the invention will become apparent upon consideration of the following detailed description of preferred embodiments thereof.

#### DETAILED DESCRIPTION

The novel products and processes provided by the present invention are illustrated in the following examples which relate to manipulations involved in securing yeast cell synthesis and secretion of polypeptide substances having one or more of the biological activities of human  $\beta$ -endorphin. More specifically, Examples 1 through 7 relate to: (1) the isolation of an Mfu structural gene as a DNA fragment from a yeast

EXAMPLE 2

A DNA sequence coding for human [Leu<sup>5</sup>]  $\beta$ -endorphin polypeptide was synthesized and constructed according to the procedures of co-pending U.S. Patent Application Serial No. 375,493 filed May 6, 1982 by Stabinsky. The specific sequence constructed is set out in Table II below. Terminal base pair sequences outside the coding region are provided to facilitate insertion into the MfA structural gene as described, *infra*.

TABLE II

HindIII	Tyr	Gly	Gly	Phe	Leu	Thr	Ser	Glu	Lys	Ser	Gln	Thr
	AGCT	TAC	GGT	GGT	TTC	TTC	ACC	TCT	GAA	AAG	TCT	CAA
	ATG	CCA	CCA	AAG	AAC	TGG	AGA	CTT	TTC	AGA	GTT	TGA
	Pro	Lys	Val	Thr	Leu	Phe	Lys	Asn	Ala	Ile	Ile	Lys
	CCA	TTG	GTT	ACT	TTG	TTC	AAG	AAC	GCT	ATC	ATC	AAG
	GGT	AAC	CAA	TGA	AAC	AAG	TTC	TTG	CGA	TAG	TAG	TTG
												CGA
	Tyr	Lys	Lys	Gly	Glu	Ter	Ter					
	TAC	AAG	AAG	GGT	GAA	TAA	TAA	GCTTG				
	ATG	TTC	TTC	CCA	CTT	ATT	ATT	CGAACCTAG				
									HindII	BamHI		

The constructed sequence was cloned into the Rf M13mp9 which had been cut with HindIII and BamHI and the sequence was confirmed. The resulting Rf M13 DNA, designated M13/8End-9, was purified.

EXAMPLE 3

Plasmid pofc was digested with HindIII to delete three of the four MfA coding regions. As may be noted from the sequence of the protein-coding region of the MfA structural gene in Table I, after such endonuclease treatment there remained a HindIII sticky end

at the terminal portion of the first of the "spacer" amino acid sequences (Ala<sup>89</sup>) and a HindIII sticky end just before the final MfA sequence (Trp<sup>153</sup>).

M13/8End-9, containing the [Leu<sup>5</sup>]  $\beta$ -endorphin gene, was similarly digested with HindIII and the resulting 107 base pair fragment was purified and ligated into the HindIII cleaved pofc to generate plasmid pofE. The DNA sequence thus generated is seen to code for synthesis of a new hybrid polypeptide. In the new hybrid polypeptide, there is included, in the carboxyl terminal portion, an exogenous polypeptide, i.e., [Leu<sup>5</sup>]  $\beta$ -endorphin. In the new hybrid polypeptide, there are included sequences of amino acid residues duplicative of one or more sequences which are extant in the amino terminal region of an endogenous polypeptide precursor of a selected yeast-secreted polypeptide (i.e., MfA) and which are normally proteolytically cleaved from the yeast-secreted polypeptide portion of the precursor prior to secretion.

It may be here noted that in an alternative construction available according to the invention, a tandem repeating  $\beta$ -endorphin gene or other selected gene might be constructed and inserted into the HindIII cleaved pofc. In such a tandem repeating gene construction, the termination codons of the first  $\beta$ -endorphin coding sequence would be deleted and the first coding sequence would be separated from the second sequence by, e.g., a DNA sequence coding for part or all of one of the alternative MfA "spacer" polypeptide forms. It would be preferred that alternative codons be employed in the region joining the spacer to the second  $\beta$ -endorphin sequence so that no HindIII restriction site would remain. Upon insertion as above, the novel DNA sequence would code for a hybrid polypeptide which further included a normally proteolytically cleaved endogenous yeast sequence in its carboxyl terminal region, i.e.,



between two  $\beta$ -endorphin analog polypeptides. Similarly, multiple repeats of a selected exogenous gene may be incorporated separately by part or all of any of the variant spacers.

#### EXAMPLE 4

Plasmid p $\alpha$ E was digested with BamHI and the small fragment obtained was ligated into a high copy number yeast/*E.coli* shuttle vector pGT41 (cut with BamHI) to form plasmid p $\gamma$  $\alpha$ E (ATCC No. 40068) which was amplified in *E.coli*.

#### EXAMPLE 5

Plasmid p $\gamma$  $\alpha$ E was employed to transform a suitable  $\alpha$ , Leu<sup>2</sup> strain of *Saccharomyces cerevisiae* (GM3C-2) wherein the Leu<sup>2</sup> phenotype allowed selection of transformants. Transformed cells were grown in culture at 30°C in 0.67 Yeast Nitrogen Base without amino acids (Difco), 2% glucose, 1% histidine and 1% tryptophan. Additionally, strain GM3C-2 transformed with a plasmid identical to p $\gamma$  $\alpha$ E, with the exception that the  $\beta$ -endorphin gene was in the opposite orientation, was cultured under identical conditions as a control.

#### EXAMPLE 6

Cultures from transformed and control cells were collected, centrifuged, and the supernatants tested for the presence of  $\beta$ -endorphin activity by means of a competitive radioimmunoassay for human  $\beta$ -endorphin (New England Nuclear Catalog No. NEK-003). No activity at all was determined in the control media, while significant  $\beta$ -endorphin activity, on an order representing 200 micrograms of product per O.D. liter, was found in

the media from cultured growth of transformed cells.

HPLC analysis of the concentrated active media revealed three major RIA activity peaks. The most prominent peak, representing approximately one-third of the total  $\beta$ -endorphin activity, was isolated and amino acid sequencing revealed an essentially pure preparation of a polypeptide duplicating the sequence of the final 12 amino acid residues of human  $\beta$ -endorphin. Experimental procedures are under way to determine whether the 12 amino acid product is the result of intracellular proteolytic processing by the transformed cells or is an artifact generated by extracellular proteolytic cleavage occurring during handling of the culture medium. If the latter proves to be the case, protease inhibitors will be added to the medium in future isolative processing.

#### EXAMPLE 7

In order to determine whether secretory processing of yeast synthesized  $\beta$ -endorphin analog by transformed cells will be facilitated by reduction of the quantities of hybrid polypeptide produced, a single copy ("centromere") plasmid p $\gamma$  $\alpha$ E (ATCC No. 40069) has been constructed with an inserted BamHI fragment from p $\alpha$ E. Analysis of cell media of yeast transformed with this vector is presently under way.

In further experimental studies, the potential secretory rate limiting effects of available secretory processing enzymes will be determined. In one such procedure, yeast cells transformed with vectors of the invention will also be transformed to incorporate an *ste13* gene as described in Julius, et al., supra, so as to provide over-production of the heat stable dipeptidyl aminopeptidase believed to be involved in M $\beta$  secretory processing.

While the foregoing illustrative examples relate to the construction of DNA sequences coding for "signal" and "pro" and "spacer" polypeptide sequences extant in the polypeptide precursor of MFa, it is expected that beneficial results may be secured when only one or two such sequences are coded for or when only a portion of such sequences (e.g., only the Lys-Arg portion of a spacer) are coded for. Similarly, while the yeast strain selected for secretory expression of exogenous polypeptide products was of the  $\alpha$  phenotype, it is not necessarily the case that cells of the  $\alpha$  phenotype would be unsuitable hosts since the essential secretory and processing activity may also be active in  $\beta$  cells. Finally, while expression of novel DNA sequences in the above illustrative examples was under control of an endogenous MFa promoter/regulator within the copy of the cloned genomic MFa-specifying DNA, it is expected that other yeast promoter DNA sequences may be suitably employed. Appropriate promoters may include yeast PGK and ADH-1 promoters or the G3PDH promoter of applicant's co-pending U.S. Patent Application Serial No. 412,707, filed August 3, 1982.

Although the above examples relate specifically to constructions involving DNA sequences associated with endogenous MFa secretion into yeast cell growth media, it will be understood that the successful results obtained strongly indicate the likelihood of success when DNA sequences associated with other yeast-secreted polypeptides (as noted above) are employed. In this regard, substantial benefits in polypeptide isolation are expected to attend intracellular secretory processing of exogenous polypeptides into yeast periplasmic spaces as well as into yeast growth media.

Numerous modifications and variations in the invention as represented by the above illustrative examples are expected to occur to those skilled in the art,

and consequently only such limitations as appear in the appended claims should be placed upon the invention.

The features disclosed in the foregoing description, in the following claims and/or in the accompanying drawings may, both separately and in any combination thereof, be material for realizing the invention in 10 diverse forms thereof.

15

20

25

30

35

## WHAT IS CLAIMED IS:

1. A DNA sequence coding for yeast cell synthesis of a hybrid polypeptide,  
 a portion of the carboxyl terminal region of said hybrid polypeptide comprising an exogenous polypeptide to be secreted by those yeast cells in which the hybrid polypeptide is synthesized,  
 a portion of the amino terminal region of said hybrid polypeptide comprising an endogenous yeast polypeptide characterized by including a sequence of amino acid residues duplicative of one or more sequences (1) extant in the amino terminal region of an endogenous polypeptide precursor of a selected yeast-secreted polypeptide, and (2) normally proteolytically cleaved from the yeast-secreted polypeptide portion of the endogenous polypeptide precursor prior to secretion.

2. A DNA sequence according to claim 1 wherein the endogenous yeast polypeptide comprising a portion of the amino terminal region of said hybrid polypeptide coded for includes a sequence of amino acid residues duplicative of one or more sequences extant in the amino terminal region of a polypeptide precursor of a yeast-secreted polypeptide selected from the group consisting of:

mating factor  $\alpha$ , mating factor  $\beta$ , pheromone peptidase, killer toxin, invertase repressible acid phosphatase, constitutive acid phosphatase,  $\alpha$ -galactosidase, L-asparaginase, exo-1,3- $\beta$ -glucanase, and endo-1,3- $\beta$ -glucanase.

3. A DNA sequence according to claim 2 wherein the endogenous yeast polypeptide comprising a portion of the amino terminal region of said hybrid polypeptide coded for includes a sequence of amino acid residues

duplicative of one or more sequences extant in the amino terminal region of the polypeptide precursor of yeast mating factor  $\alpha$ .

4. A DNA sequence according to claim 3 wherein an amino acid sequence duplicated is as follows:  
 $\text{NH}_2\text{-Met-Arg-Phe-Pro-Ser-Ile-Phe-Thr-Ala-Val-Leu-Phe-Ala-Ala-Ser-Ser-Ala-Leu-Ala-Ala-Pro-Val-COO-}$ .

5. A DNA sequence according to claim 3 wherein an amino acid sequence duplicated in said hybrid polypeptide is as follows:

$\text{-NH-Asn-Thr-Thr-Thr-Glu-Asp-Glu-Thr-Ala-Gln-Ile-Pro-Ala-Glu-Ala-Val-Ile-Gly-Tyr-Ser-Asp-Leu-Glu-Gly-Asp-Phe-Asp-Val-Ala-Val-Leu-Pro-Phe-Ser-Asn-Ser-Thr-Asn-Asn-Gly-Leu-Leu-Phe-Ile-Asn-Thr-Thr-Ile-Ala-Ser-Ile-Ala-Ala-Lys-Glu-Glu-Gly-Val-Ser-Leu-Asp-COO-}$ .

6. A DNA sequence according to claim 3 wherein an amino acid sequence duplicated in said hybrid polypeptide is selected from the group consisting of:

$\text{-NH-Lys-Arg-Glu-Ala-Glu-Ala-COO-}$ , or  
 $\text{-NH-Lys-Arg-Glu-Ala-Glu-Ala-COO-}$ , or  
 $\text{-NH-Lys-Arg-Glu-Ala-Asp-Ala-Glu-Ala-COO-}$ .

7. A DNA sequence according to claim 3 wherein an amino acid sequence duplicated in said hybrid polypeptide is as follows:

$\text{NH}_2\text{-Met-Arg-Phe-Pro-Ser-Ile-Phe-Thr-Ala-Val-Leu-Phe-Ala-Ala-Ser-Ser-Ala-Leu-Ala-Ala-Pro-Val-Asn-Thr-Thr-Glu-Asp-Glu-Thr-Ala-Gln-Ile-Pro-Ala-Glu-Ala-Val-Ile-Gly-Tyr-Ser-Asp-Leu-Glu-Gly-Asp-Phe-Asp-Val-Ala-Val-Leu-Pro-Phe-Ser-Asn-Ser-Thr-Asn-Asn-Gly-Leu-Leu-Phe-Ile-Asn-Thr-Thr-}$

70 Ile-Ala-Ser-Ile-Ala-Ala-Lys-Glu-Gly-Val-Ser-Leu-Asp-  
80 Lys-Arg-Glu-Ala-Glu-Ala-COO-.

5 8. A DNA sequence according to claim 1 wherein  
a portion of the carboxyl terminal region of said hybrid  
polypeptide coded for also comprises an endogenous poly-  
peptide including a sequence of amino acid residues  
duplicative of one or more sequences (1) extant in the  
10 carboxyl terminal region of an endogenous polypeptide  
precursor of a yeast-secreted polypeptide, and (2)  
normally proteolytically cleaved from the yeast-secreted  
portion of the precursor polypeptide prior to secretion.

15 9. A DNA sequence according to claim 8 wherein  
the endogenous yeast polypeptide comprising a portion  
of the carboxyl terminal region of said hybrid polypep-  
tide coded for includes a sequence of amino acid residues  
duplicative of one or more sequences extant in the carb-  
20 oxy terminal region of a polypeptide precursor of yeast  
mating factor  $\alpha$ .

10. A DNA sequence according to claim 9  
wherein an amino acid sequence duplicated in said hybrid  
25 polypeptide is selected from the group consisting of:  
-NH-Lys-Arg-Glu-Ala-Glu-Ala-Glu-Ala-COO-; and  
-NH-Lys-Arg-Glu-Ala-Asp-Ala-Glu-Ala-COO-.

11. A DNA sequence according to claim 1  
30 wherein the exogenous polypeptide in the carboxyl term-  
inal region of the hybrid polypeptide coded for is a  
mammalian polypeptide.

12. A DNA sequence according to claim 11  
35 wherein the mammalian polypeptide is human  $\beta$ -endorphin.

13. A yeast cell transformation vector com-  
prising a DNA sequence according to claim 1.

5 14. A yeast cell transformation vector accord-  
ing to claim 13 wherein expression of said DNA sequence  
is regulated by a promoter/regulator DNA sequence dupli-  
cative of that regulating endogenous expression of the  
selected precursor polypeptide.

10 15. A yeast cell transformation vector accord-  
ing to claim 13 which is plasmid pYae, ATCC No. 40068.

15 16. A yeast cell transformation vector accord-  
ing to claim 13 which is plasmid pYcaE, ATCC No. 40069.

17. A method for production of a selected  
exogenous polypeptide in yeast cells comprising:  
transforming yeast cells with a DNA vector  
according to claim 13;

20 incubating yeast cells so transformed under  
conditions facilitative of yeast cell growth and multi-  
plication, the transcription and translation of the DNA  
sequence comprising said vector, and the intracellular  
processing toward secretion of said selected exogenous  
25 polypeptide into the yeast cell periplasmic space and/or  
the yeast cell growth medium; and  
isolating the selected exogenous polypeptide  
from the yeast cell periplasmic space and/or the yeast  
cell growth medium.

30 18. A method for securing production in yeast  
cells of polypeptide products displaying one or more of  
the biological activities of human  $\beta$ -endorphin comprising:  
transforming yeast cells with a DNA vector  
35 according to claim 15 or claim 16;

incubating yeast cells so transformed under conditions facilitative of yeast cell growth and multiplication, transcription and translation of said DNA sequence coding for a hybrid, [Leu<sup>5</sup>]  $\beta$ -endorphin-containing, polypeptide in said vector, and the intracellular processing toward secretion of polypeptide products displaying one or more of the biological activities of  $\beta$ -endorphin into the yeast cell growth medium; and

isolating the desired polypeptide products from the yeast cell growth medium.

15

20

25

30

35

European Patent  
Office

## EUROPEAN SEARCH REPORT

0123294

Application Number

EP 84104456.3

DOCUMENTS CONSIDERED TO BE RELEVANT			Request to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim		
A, D	CELL, vol. 30, no. 3, October 1982, Cambridge, Mass. J. KURJAN et al. "Structure of a Yeast Pheromone Gene (MRC): A Putative $\alpha$ -Factor Precursor Contains Four Tandem Copies of Mature $\alpha$ -Factor" pages 933-943 • Summary, page 937 • --	1-7	C 12 N 15/00 C 12 P 21/00	
A, D	CELL, vol. 32, no. 3, March 1983, Cambridge, Mass. D. JULIUS et al. "Yeast $\alpha$ Factor is Processed from a Larger Precursor Polypeptide: The Essential Role of a Membrane-Bound Dipeptidyl Aminopeptidase" pages 839-852 • Summary • --	1, 2		
A	EP - A2 - O 035 781 (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA) • Abstract • ----	1, 12, 18	C 12 N C 12 P	
The present search report has been drawn up for all claims				
Place of search VIENNA		Date of completion of the search 30-07-1984	Examiner WOLF	
CATEGORY OF CITED DOCUMENTS				
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : intermediate document P : intermediate document				
Z : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date of the application D : document cited in the application L : document cited for other reasons S : member of the same patent family, corresponding document				

EP Form 1001

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**